At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06938 RIBOLIFE-B
Market Closed 05-29 16:08:25
58.200
+3.250
+5.91%
High58.200
Low53.200
Vol101.19K
Open54.800
D1 Closing54.950
Amplitude9.10%
Mkt Cap9.93B
Tradable Cap9.93B
Total Shares170.55M
T/O5.59M
T/O Rate0.06%
Tradable Shares170.55M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Suzhou Ribo submits EMA Phase 2 trial application for RBD1119 in coronary artery disease
Suzhou Ribo Life Science Co Ltd is a China-based company primarily engaged in the oligonucleotide research and development, with a focus on small interfering ribonucleic acid (siRNA) therapeutics. The Company’s main business is engaged in the oligonucleotide drug innovation focused on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The Company’s drug pipelines include RBD4059, RBD5044, RBD7022, RBD7007, RBD2080, RBD1119, RBD1016 and others. The Company mainly conducts its business in the domestic market.